Novavax releases first late-trial COVID-19 vaccine data; reports 90.4% efficacy, strong protection against variants
Novavax today announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy. The phase 3 trial, which enrolled more than 29,000 participants across the U.S. and Mexico, also demonstrated the vaccine to be safe. Additionally, the Novavax vaccine maintained a 93% efficacy against COVID-19 variants that emerged between January and April of this year.
The vaccine uses recombinant nanoparticle technology to generate a coronavirus spike protein-generated antigen. The company says the vaccine is stored and stable at 2-8 degrees Celsius (about 35-46 degrees Fahrenheit), enabling the use of existing vaccine supply chain channels for distribution.
Related News Articles
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…